Sonexa Therapeutics

Sonexa Therapeutics, Inc., is a privately-held pharmaceutical company committed to the development of drug treatments for Alzheimer's disease (AD) and related disorders.

According to the World Alzheimer Report (2009), an estimated 35.6 million people worldwide will be living with dementia in 2010. This number is estimated to nearly double every 20 years.

In 2009 there were an estimated 5.3 million people suffering with Alzheimer's disease in the United States at an annual cost of $148 billion dollars with nearly 10 million people functioning as unpaid caregivers. There is a new case of Alzheimer's disease diagnosed every 70 seconds and Alzheimer's disease is the 6th leading cause of death in the U.S.*

*Alzheimer's Association. (2009). Alzheimer's Facts and Figures. Retrieved December 17, 2009, from Alzheimer's Association.